Insight

$Raul Cordoba: Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma$

Photo generated from www.thelancet.com

Jun 19, 2024, 06:53

Raul Cordoba: Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma

Raul Cordoba shared on X:

“HOT OFF THE PRESS!

Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study.”

Read further
Source: Raul Cordoba/X

Raúl Córdoba Mascuñano, MD, PhD is a specialist in hematology and hemotherapy. He is the Coordinator of the Lymphoma Unit at University Hospital Fundación Jiménez Díaz, Madrid, Spain. He is the principal investigator for numerous clinical trials for non-Hodgkin lymphoma, Hodgkin lymphoma, chronic lymphocytic leukemia and other chronic lymphoproliferative syndromes. He is a member of the ethical review board at his current workplace.

cancer Cancer research EPCORE NHL-1 Epcoritamab Epcoritamab monotherapy follicular lymphoma lymphoma multicentre study OncoDaily Oncology Raul Cordoba

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Special Coverage